Skip to content
PAD
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFU’s
About Us
About Us
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator Initiated
Research
Contact Us
PAD
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFU’s
About Us
About Us
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator Initiated
Research
Contact Us
Search
Read about Endologix
in the news
Embrace the evidence.
The Latest:
Jul 2
3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease
See Release
All News
Archives
All
2026
2025
2024
2023
2022
2021
Oct 20
ELEVATE IDE Study highlights the Safety and Effectiveness of the ALTO® Abdominal Stent Graft System in One-year Results; Data to Be Presented at 2022 VEITHsymposium
Oct 11
Endologix Submits Premarket Approval (PMA) Application to FDA for the DETOUR™ System.
Aug 4
Endologix Receives CE Mark Certification under EU MDR for AFX®2 Endovascular AAA System
Jun 23
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting
Nov 23
Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next
